Oncorus, Inc. – NASDAQ:ONCR
Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Oncorus stock price monthly change
+500.00%
month
Oncorus stock price quarterly change
+344.05%
quarter
Oncorus stock price yearly change
-54.18%
year
Oncorus key metrics
Market Cap | N/A |
Enterprise value | N/A |
P/E | -0.04 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.05 |
PEG ratio | N/A |
EPS | -3.63 |
Revenue | N/A |
EBITDA | -56.17M |
Income | -94.26M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOncorus stock price history
Oncorus stock forecast
Oncorus financial statements
| Jun 2022 | 0 | -19.54M | |
|---|---|---|---|
| Sep 2022 | 0 | -19.94M | |
| Dec 2022 | 0 | -21.49M | |
| Mar 2023 | 0 | -33.28M |
| 2025 | 0 | -16.85M |
|---|
Analysts Price target
Financials & Ratios estimates
| Jun 2022 | 182540000 | 84.53M | 46.31% |
|---|---|---|---|
| Sep 2022 | 164365000 | 84.36M | 51.33% |
| Dec 2022 | 145586000 | 85.06M | 58.43% |
| Mar 2023 | 109753000 | 78.63M | 71.64% |
| Jun 2022 | -13.25M | 2.98M | 19.56M |
|---|---|---|---|
| Sep 2022 | -10.85M | -32.37M | 0 |
| Dec 2022 | -14.14M | -1.74M | 29K |
| Mar 2023 | -17.44M | 12.95M | 0 |
Oncorus alternative data
| Aug 2023 | 64 |
|---|---|
| Sep 2023 | 64 |
| Oct 2023 | 64 |
| Nov 2023 | 64 |
| Dec 2023 | 64 |
| Jan 2024 | 64 |
| Feb 2024 | 64 |
| Mar 2024 | 64 |
| Apr 2024 | 64 |
| May 2024 | 64 |
| Jun 2024 | 64 |
| Jul 2024 | 64 |
Oncorus other data
100.00%
+39.86%
of ONCR is owned by hedge funds
17
-14
9.19M
-6.42M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2022 | 49000 | 0 |
| Dec 2022 | 0 | 438078 |
| Patent |
|---|
Application Filling date: 3 Jan 2020 Issue date: 21 Apr 2022 |
Application Filling date: 13 Nov 2019 Issue date: 30 Dec 2021 |
Application Filling date: 28 Dec 2018 Issue date: 25 Mar 2021 |
Application Filling date: 13 Jul 2018 Issue date: 16 Jul 2020 |
Application Filling date: 26 Jul 2018 Issue date: 2 Jul 2020 |
Application Filling date: 28 Jan 2020 Issue date: 21 May 2020 |
Application Filling date: 10 Jul 2019 Issue date: 14 May 2020 |
Grant Filling date: 25 Oct 2018 Issue date: 31 Mar 2020 |
Grant Filling date: 27 Jul 2018 Issue date: 27 Aug 2019 |
-
When is Oncorus's next earnings date?
Unfortunately, Oncorus's (ONCR) next earnings date is currently unknown.
-
Does Oncorus pay dividends?
No, Oncorus does not pay dividends.
-
What is Oncorus's stock symbol?
Oncorus, Inc. is traded on the NASDAQ under the ticker symbol "ONCR".
-
What is Oncorus's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Oncorus?
Shares of Oncorus can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Oncorus's key executives?
Oncorus's management team includes the following people:
- Mr. Stephen W. Harbin Chief Operating Officer & Chief of Staff(age: 67, pay: $815,090)
- Dr. Theodore T. Ashburn Pres, Chief Executive Officer & Director(age: 58, pay: $760,130)
- Dr. Christophe Queva Ph.D. Chief Scientific Officer & Senior Vice President of Research(age: 57, pay: $545,580)
- Dr. Mitchell H. Finer Ph.D. Co-Founder & Executive Chairman(age: 66, pay: $126,650)
-
Is Oncorus founder-led company?
Yes, Oncorus is a company led by its founder Dr. Mitchell H. Finer Ph.D..
-
How many employees does Oncorus have?
As Jul 2024, Oncorus employs 64 workers.
-
When Oncorus went public?
Oncorus, Inc. is publicly traded company for more then 4 years since IPO on 2 Oct 2020.
-
What is Oncorus's official website?
The official website for Oncorus is oncorus.com.
-
Where are Oncorus's headquarters?
Oncorus is headquartered at 50 Hampshire Street, Cambridge, MA.
-
How can i contact Oncorus?
Oncorus's mailing address is 50 Hampshire Street, Cambridge, MA and company can be reached via phone at 857 320 6400.
Oncorus company profile:
Oncorus, Inc.
oncorus.comExchange:
NASDAQ
Full time employees:
64
Industry:
Biotechnology
Sector:
Healthcare
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
50 Hampshire Street
Cambridge, MA 02139
Cambridge, MA 02139
CIK: 0001671818
ISIN: US68236R1032
CUSIP: 68236R103
